NASDAQ:XNCR - Xencor Stock Price, Forecast & News

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Xencor Inc (NASDAQ:XNCR) announced its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.58) by $0.40. The biopharmaceutical company had revenue of $21.76 million for the quarter, compared to the consensus estimate of $4.62 million. Xencor had a net margin of 21.60% and a return on equity of 5.84%. View Xencor's Earnings History.

Xencor is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Xencor.

Xencor will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

11 brokers have issued 12-month price objectives for Xencor's stock. Their forecasts range from $21.00 to $67.00. On average, they anticipate Xencor's stock price to reach $44.44 in the next twelve months. This suggests a possible upside of 26.3% from the stock's current price. View Analyst Price Targets for Xencor.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xencor.

News stories about XNCR stock have trended extremely negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Xencor earned a news sentiment score of -4.2 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Xencor.

Xencor saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,820,000 shares, an increase of 5.9% from the January 15th total of 4,550,000 shares. Based on an average trading volume of 341,600 shares, the days-to-cover ratio is currently 14.1 days. Currently, 8.6% of the company's shares are sold short. View Xencor's Current Options Chain.

Some companies that are related to Xencor include Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR) and Nektar Therapeutics (NKTR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Cypress Semiconductor (CY), Exelixis (EXEL), Fossil Group (FOSL), Apollo Global Management (APO), Immunomedics (IMMU), Intel (INTC), Abercrombie & Fitch (ANF) and Ciena (CIEN).

Xencor's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), State Street Corp (3.50%), Geode Capital Management LLC (1.21%), Goldman Sachs Group Inc. (1.03%), Loomis Sayles & Co. L P (1.03%) and Bank of New York Mellon Corp (0.96%). Company insiders that own Xencor stock include Bassil I Dahiyat, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.

XNCR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, PNC Financial Services Group Inc., Franklin Resources Inc., Rafferty Asset Management LLC, First Trust Advisors LP, Citigroup Inc., Arizona State Retirement System and Bank of America Corp DE. Company insiders that have sold Xencor company stock in the last year include John J Kuch, John R Desjarlais and John S Stafford III. View Insider Buying and Selling for Xencor.

XNCR stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Man Group plc, Raymond James & Associates, Los Angeles Capital Management & Equity Research Inc., Great West Life Assurance Co. Can, Panagora Asset Management Inc. and DCF Advisers LLC. View Insider Buying and Selling for Xencor.

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XNCR stock can currently be purchased for approximately $35.20.

Xencor has a market capitalization of $2.00 billion and generates $40.60 million in revenue each year. The biopharmaceutical company earns $-70,410,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Xencor employs 156 workers across the globe.View Additional Information About Xencor.

The official website for Xencor is http://www.xencor.com/.

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]